Corrigendum: Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance (Nature (2017) 546 (431-435) DOI: 10.1038/nature22794);Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

Nature

Volumn 546, Issue 7658, 2017, Pages 431-435

  Shaffer, Sydney M ^a,b   Dunagin, Margaret C ^a   Torborg, Stefan R ^a,c   Torre, Eduardo A ^a,b   Emert, Benjamin ^b,c   Krepler, Clemens ^d   Beqiri, Marilda ^d   Sproesser, Katrin ^d   Brafford, Patricia A ^d   Xiao, Min ^d   Eggan, Elliott ^d   Anastopoulos, Ioannis N ^b   Vargas Garcia, Cesar A ^b   Singh, Abhyudai ^e   Nathanson, Katherine L ^e   Herlyn, Meenhard ^b   Raj, Arjun ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d WISTAR INSTITUTE   (United States)

^e University of Delaware   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APCDD1 PROTEIN; AXL PROTEIN; CYCLIN A2; CYSTEINE RICH PROTEIN 61; EPIDERMAL GROWTH FACTOR RECEPTOR; LOXL2 PROTEIN; MESSENGER RNA; NERVE GROWTH FACTOR RECEPTOR; NRG1 PROTEIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN; PROTEIN C JUN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SOX10; TRANSCRIPTION FACTOR TEAD; UNCLASSIFIED DRUG; VEMURAFENIB; WNT5A PROTEIN; DNA BINDING PROTEIN; EGFR PROTEIN, HUMAN; GENETIC MARKER; INDOLE DERIVATIVE; NUCLEAR PROTEIN; ONCOPROTEIN; SOX10 PROTEIN, HUMAN; SULFONAMIDE; TEAD1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

CANCER; CELLS AND CELL COMPONENTS; DRUG; DRUG RESISTANCE; GENE EXPRESSION; GENETIC MARKER; MUTATION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL REPROGRAMMING TECHNIQUE; CELLS BY BODY ANATOMY; CONTROLLED STUDY; EPIGENETICS; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; LUNG CANCER; MALIGNANT NEOPLASM; MELANOCYTE; MELANOMA; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; DEFICIENCY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC MARKER; GENETIC TRANSCRIPTION; GENETICS; MALE; METABOLISM; NUCLEAR REPROGRAMMING; PATHOLOGY; SINGLE CELL ANALYSIS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELLULAR REPROGRAMMING; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INDOLES; MALE; MELANOMA; NUCLEAR PROTEINS; ONCOGENE PROTEIN P65(GAG-JUN); RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SINGLE-CELL ANALYSIS; SOXE TRANSCRIPTION FACTORS; SULFONAMIDES; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85020929776     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature25162     Document Type: Erratum

References (35)

1. Trunzer, K. et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J. Clin. Oncol. 31, 1767-1774 (2013).
2. Garraway, L. A. & Jänne, P. A. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2, 214-226 (2012).
3. Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977 (2010).
4. Krepler, C. et al. Personalized preclinical trials in BRAF inhibitor resistant patient-derived xenograft models identify second-line combination therapies. Clin. Cancer Res. 22, 1592-1602 (2015).
5. Spencer, S. L., Gaudet, S., Albeck, J. G., Burke, J. M. & Sorger, P. K. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 459, 428-432 (2009).
6. Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80 (2010).
7. Gupta, P. B. et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146, 633-644 (2011).
8. Pisco, A. O. & Huang, S. Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: 'What does not kill me strengthens me'. Br. J. Cancer 112, 1725-1732 (2015).
9. Ramirez, M. et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat. Commun. 7, 10690 (2016).
10. Nguyen, A., Yoshida, M., Goodarzi, H. & Tavazoie, S. F. Highly variable cancer subpopulations that exhibit enhanced transcriptome variability and metastatic fitness. Nat. Commun. 7, 11246 (2016).
11. Symmons, O. & Raj, A. What's luck got to do with it: single cells, multiple fates, and biological nondeterminism. Mol. Cell 62, 788-802 (2016).
12. Luria, S. E. & Delbrück, M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28, 491-511 (1943).
13. Webster, M. R. & Weeraratna, A. T. A Wnt-er migration: the confusing role of β -catenin in melanoma metastasis. Sci. Signal. 6, pe11 (2013).
14. Müller, J. et al. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat. Commun. 5, 5712 (2014).
15. Sun, C. et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508, 118-122 (2014).
16. Ramsdale, R. et al. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. Sci. Signal. 8, ra82 (2015).
17. Padovan-Merhar, O. et al. Single mammalian cells compensate for differences in cellular volume and DNA copy number through independent global transcriptional mechanisms. Mol. Cell 58, 339-352 (2015).
18. Lubeck, E., Coskun, A. F., Zhiyentayev, T., Ahmad, M. & Cai, L. Single-cell in situ RNA profiling by sequential hybridization. Nat. Methods 11, 360-361 (2014).
19. Jiang, L., Chen, H., Pinello, L. & Yuan, G.-C. GiniClust: detecting rare cell types from single-cell gene expression data with Gini index. Genome Biol. 17, 144 (2016).
20. Roesch, A. et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell 23, 811-825 (2013).
21. Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189-196 (2016).
22. Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods 10, 1213-1218 (2013).
23. Verfaillie, A. et al. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nat. Commun. 6, 6683 (2015).
24. O'Connell, M. P. et al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov. 3, 1378-1393 (2013).
25. Viswanathan, V. S. & Schreiber, S. Dependency of a therapy-resistant high-mesenchymal state of cancer cells on a lipid peroxidase pathway. Nature (in the press) (2017).
26. Hata, A. N. et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22, 262-269 (2016).
27. Liao, D., Estévez-Salmerón, L. & Tlsty, T. D. Conceptualizing a tool to optimize therapy based on dynamic heterogeneity. Phys. Biol. 9, 065005 (2012).
28. Das Thakur, M. et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494, 251-255 (2013).
29. Seghers, A. C., Wilgenhof, S., Lebbé, C. & Neyns, B. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res. 22, 466-472 (2012).
30. Raj, A., van den Bogaard, P., Rifkin, S. A., van Oudenaarden, A. & Tyagi, S. Imaging individual mRNA molecules using multiple singly labeled probes. Nat. Methods 5, 877-879 (2008).
31. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows- Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
32. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013).
33. Garrison, E. & Marth, G. Haplotype-based variant detection from short-read sequencing. Preprint at https://arxiv.org/abs/1207.3907 (2012).
34. 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56-65 (2012).
35. Battich, N., Stoeger, T. & Pelkmans, L. Control of transcript variability in single mammalian cells. Cell 163, 1596-1610 (2015).